Modulation of neuroinflammation and pathology in the 5XFAD mouse model of Alzheimer's disease using a biased and selective beta-1 adrenergic receptor partial agonist

NEUROPHARMACOLOGY

卷:116

Article

Ardestani, Pooneh Memar¹  Evans, Andrew K.¹  Yi, Bitna¹  Nguyen, Tiffany¹  Coutellier, Laurence^1,2,3  Shamloo, Mehrdad¹ 

[1] Stanford Univ, Sch Med, Dept Neurosurg, 1050 Arastradero Rd,Bldg A, Palo Alto, CA 94304 USA

[2] Ohio State Univ, Dept Psychol, Columbus, OH 43210 USA

[3] Ohio State Univ, Dept Neurosci, Columbus, OH 43210 USA

关键词: Alzheimer's disease;    Neuroinflammation;    Amyloid beta;    Xamoterol;    Beta-1 adrenergic receptor;    5XFAD;   

DOI  :  10.1016/j.neuropharm.2017.01.010

来源: Elsevier

【 摘 要 】

Degeneration of noradrenergic neurons occurs at an early stage of Alzheimer's Disease (AD). The noradrenergic system regulates arousal and learning and memory, and has been implicated in regulating neuroinflammation. Loss of noradrenergic tone may underlie AD progression at many levels. We have previously shown that acute administration of a partial agonist of the beta-1 adrenergic receptor (ADRB1), xamoterol, restores behavioral deficits in a mouse model of AD. The current studies examined the effects of chronic low dose xamoterol on neuroinflammation, pathology, and behavior in the pathologically aggressive 5XFAD transgenic mouse model of AD. In vitro experiments in cells expressing human beta adrenergic receptors demonstrate that xamoterol is highly selective for ADRB1 and functionally biased for the cAMP over the (beta-arrestin pathway. Data demonstrate ADRB1-mediated attenuation of TNF-alpha production with xamoterol in primary rat microglia culture following LPS challenge. Finally, two independent cohorts of 5XFAD and control mice were administered xamoterol from approximately 4.0-6.5 or 7.0-9.5 months, were tested in an array of behavioral tasks, and brains were examined for evidence of neuroinflammation, and amyloid beta and tau pathology. Xamoterol reduced mRNA expression of neuroinflammatory markers (Iba1, CD74, CD14 and TGF beta) and immunohistochemical evidence for microgliosis and astrogliosis. Xamoterol reduced amyloid beta and tau pathology as measured by regional immunohistochemistry. Behavioral deficits were not observed for 5XFAD mice. In conclusion, chronic administration of a selective, functionally biased, partial agonist of ADRB1 is effective in reducing neuroinflammation and amyloid beta and tau pathology in the 5XFAD model of AD. (C) 2017 Elsevier Ltd. All rights reserved.

【 授权许可】

Free